Kimberly Rawls
Family · Pine Bluff, ARNPI 1174001382
Payments from drug & device makers
Across 109 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$311
- AbbVie$277
- GSK$156
- Merck$151
- Lilly USA, LLC$137
- Otsuka America Pharmaceutical, Inc.$118
- plus $698 from 16 others
What the payments were for
- Food & beverage$1,850100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $311 |
| AbbVie | 16 | $277 |
| GSK | 10 | $156 |
| Merck | 8 | $151 |
| Lilly USA, LLC | 10 | $137 |
| Otsuka America Pharmaceutical, Inc. | 6 | $118 |
| Dexcom, Inc. | 5 | $101 |
| Boehringer Ingelheim | 6 | $99 |
| Bayer | 4 | $72 |
| Amgen | 4 | $68 |
| Astellas Pharma US Inc | 3 | $67 |
| AstraZeneca | 3 | $51 |
| Pfizer | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Novartis | 1 | $13 |
How this compares
$1,850 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $28,222 |
| OzempicSemaglutide | 14 | $22,243 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,534 |
| JanuviaSitagliptin Phosphate | 17 | $12,533 |
| FarxigaDapagliflozin Propanediol | 13 | $7,647 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $5,063 |
| Omeprazole | 153 | $2,202 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 13 | $1,916 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,770 |
| Levothyroxine Sodium | 122 | $1,598 |
| Atorvastatin Calcium | 177 | $1,572 |
| Gabapentin | 112 | $1,535 |
| PaxlovidNirmatrelvir/Ritonavir | 13 | $1,429 |
| Amlodipine Besylate | 257 | $1,406 |
| Losartan Potassium | 168 | $1,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $99 | $28,22222 claims |
| Novo NordiskOzempic | $311 | $22,24314 claims |
| MerckJanuvia | $151 | $12,53317 claims |
| AstraZenecaFarxiga | $51 | $7,64713 claims |
| PfizerPaxlovid | $47 | $1,42913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.
Other family in Pine Bluff
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.